Back to results
US 2026/0249029 A1Published application
Medical counter measures including dry powder formulations and associated methods
AssigneeBelhaven BioPharma Inc.
InventorsScott Lyman, Barry Bleske
Life of this patent
Estimating the term…
Abstract
Provided herein are dry powder formulations comprising at least one active pharmaceutical ingredient suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including respiratory conditions, hemodynamic collapse, seizures, migraines, and other conditions.
Claims20
A dry powder pharmaceutical composition comprising:
- galantamine or a pharmaceutical salt thereof, wherein the dry powder pharmaceutical composition provides a dose of about 5 mg to about 75 mg of the galantamine or the pharmaceutical salt thereof;
- sodium chloride, wherein the dry powder pharmaceutical composition comprises about 0.01 mg to about 5 mg of the sodium chloride;
- and
- a carrier;
- wherein the dry powder pharmaceutical composition does not include chitosan.
2 more elements
A dry powder pharmaceutical composition comprising:
- galantamine or a pharmaceutical salt thereof, wherein the dry powder pharmaceutical composition provides a dose of about 5 mg to about 75 mg of the galantamine or the pharmaceutical salt thereof;
- and
- sodium chloride, wherein the dry powder pharmaceutical composition comprises about 0.01 mg to about 5 mg of the sodium chloride;
- wherein the dry powder pharmaceutical composition does not include chitosan.
1 more element
A method of intranasally delivering a dry powder pharmaceutical composition comprising:
- intranasally administering the dry powder pharmaceutical composition;
- wherein the dry powder pharmaceutical composition comprises galantamine or a pharmaceutical salt thereof, memantine, sodium chloride, and a carrier;
- wherein the dry powder pharmaceutical composition provides a dose of about 5 mg to about 75 mg of the galantamine or the pharmaceutical salt thereof;
- wherein the dry powder pharmaceutical composition provides a dose of about 1 mg to about 30 mg of the memantine;
- wherein the dry powder pharmaceutical composition comprises about 0.01 mg to about 5 mg of the sodium chloride;
- and
- wherein the dry powder pharmaceutical composition does not include chitosan.
4 more elements
Dependencies are inferred from the claim text.